Beta
Today
Capital & Financial MarketsOperations & Footprint 11 Nov 2026

Kruger Products defers TAD tissue plant beyond 2028 as Q3 EBITDA rises 9%

Kruger Products, the Canadian tissue maker in which KP Tissue holds a 12.0% interest, has deferred the final site decision for its planned through-air-dried (TAD) tissue facility until the economic and trade environment is clearer, and no longer expects the plant to start operating in 2028. In Q3 2026 results published on 11 November, revenue rose 5.1% to USD 414.4m (CAD 589.7m) and Adjusted EBITDA rose 9.1% to USD 65.7m (CAD 93.5m); Q4 Adjusted EBITDA is expected slightly below Q3.

Why this mattersDeferring a TAD machine until trade terms settle holds back new premium tissue capacity at a producer growing its US consumer business.

  • New TAD tissue facility delayed and will not start operations in 2028 as previously planned
  • Final location decision deferred until there is greater certainty in the economic and trade environment
  • Q3 2026 revenue USD 414.4m (CAD 589.7m), up 5.1% from USD 394.3m (CAD 561.1m) a year earlier
  • Q3 2026 Adjusted EBITDA USD 65.7m (CAD 93.5m), up 9.1% year on year
  • Q3 2026 net income USD 19.5m (CAD 27.7m), up from USD 10.3m (CAD 14.6m)
  • Total liquidity USD 305.1m (CAD 434.2m) as of 30 September 2026
Kruger
Sources www2.newsfilecorp.com
Relevant to you?

Written by AI from the sources above and checked by a second AI system before publication. No human wrote or edited this story. How it is made.

Updates

  • 2026-11-12 · Edited before publication: CAD conversions wrong: 589.7/1.423 = 414.4 (not 414.5), 561.1/1.423 = 394.3 (not 394.1), 434.2/1.423 = 305.1 (not 305.2). 'Previously linked to the Sherbrooke project' not in source. Why-it-matters generalised to all Canadian producers. Topic order: the investment deferral leads.